Clinical Trials · NCT02040012
A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Unknown
- Sponsor
- Alizé Pharma
- Enrollment
- 108
- Start date
- Jul 2013
- Locations
- 1 site, United Kingdom
- Primary endpoint
- To investigate the number of adverse events of single and multiple ascending doses AZP-531 in healthy volunteers, in overweight/obese volunteers, in patients with type 2 diabetes mellitus.